1.58

0.63% -0.00

After Hours: 1.57 -0.01 -0.63%

Caribou Biosciences Inc (CRBU)

Overview News Price History Option Chain Financials Why CRBU Down? Discussions Forecast

Caribou Biosciences Inc stock is traded at $1.58, with a volume of 906.56K. It is down -0.63% in the last 24 hours and down -4.85% over the past month. Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Previous Close:

$1.58

Open:

$1.57

24h Volume:

906.56K

Relative Volume:

0.48

Market Cap:

$169.39M

Revenue:

$11.16M

Net Income/Loss:

$-148.13M

P/E Ratio:

-0.9946

EPS:

-1.5885

Net Cash Flow:

$-112.35M

1W Performance:

-5.42%

1M Performance:

-4.85%

6M Performance:

+1.29%

1Y Performance:

-20.71%

1-Day Range:

$1.55

$1.59

1-Week Range:

$1.52

$1.72

52-Week Range:

$1.38

$3.535

Caribou Biosciences Inc Stock (CRBU) Company Profile

Name

Caribou Biosciences Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

510-982-6030

Address

2929 7TH STREET, SUITE 105, BERKELEY

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

CRBU's Discussions on Twitter

Compare CRBU vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRBU Caribou Biosciences Inc	1.58	169.39M	11.16M	-148.13M	-112.35M	-1.5885
VRTX Vertex Pharmaceuticals Inc	515.57	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.86	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	986.80	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.94	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.66	39.31B	5.76B	514.49M	1.10B	4.4813

Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-03-24	Downgrade	Evercore ISI	Outperform → In-line
Nov-08-23	Initiated	Cantor Fitzgerald	Neutral
Oct-31-23	Initiated	Evercore ISI	Outperform
Jul-11-23	Initiated	Truist	Buy
Feb-18-22	Initiated	RBC Capital Mkts	Outperform
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-30-21	Initiated	H.C. Wainwright	Buy
Nov-15-21	Upgrade	Citigroup	Neutral → Buy
Aug-17-21	Initiated	BofA Securities	Buy
Aug-17-21	Initiated	Citigroup	Neutral
Aug-17-21	Initiated	SVB Leerink	Outperform

View All

Caribou Biosciences Inc Stock (CRBU) Latest News

Aug 14, 2026

Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 14, 2026

Caribou Biosciences (NASDAQ:CRBU) Price Target Cut to $5.00 by Analysts at Bank of America - MarketBeat

Aug 14, 2026

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 14, 2026

Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside - TradingView

Aug 14, 2026

Caribou Biosciences earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria

Aug 14, 2026

Aug 13, 2026

Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat

Aug 13, 2026